vs
Side-by-side financial comparison of KENNAMETAL INC (KMT) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $592.6M, roughly 1.9× KENNAMETAL INC). KENNAMETAL INC runs the higher net margin — 10.3% vs -127.8%, a 138.1% gap on every dollar of revenue. On growth, KENNAMETAL INC posted the faster year-over-year revenue change (21.8% vs -2.5%). Over the past eight quarters, KENNAMETAL INC's revenue compounded faster (4.4% CAGR vs 1.3%).
Kennametal, Inc. is a manufacturer of high-performance cutting tools and engineered components used in the aerospace, defense, transportation and oil and gas drilling industries. Its customer base is global.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
KMT vs PRGO — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $592.6M | $1.1B |
| Net Profit | $61.1M | $-1.4B |
| Gross Margin | 35.1% | 32.6% |
| Operating Margin | 13.4% | -116.0% |
| Net Margin | 10.3% | -127.8% |
| Revenue YoY | 21.8% | -2.5% |
| Net Profit YoY | 85.0% | -3093.9% |
| EPS (diluted) | $0.75 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $592.6M | — | ||
| Q4 25 | $529.5M | $1.1B | ||
| Q3 25 | $498.0M | $1.0B | ||
| Q2 25 | $516.4M | $1.1B | ||
| Q1 25 | $486.4M | $1.0B | ||
| Q4 24 | $482.1M | $1.1B | ||
| Q3 24 | $481.9M | $1.1B | ||
| Q2 24 | $543.3M | $1.1B |
| Q1 26 | $61.1M | — | ||
| Q4 25 | $33.9M | $-1.4B | ||
| Q3 25 | $23.3M | $7.5M | ||
| Q2 25 | $21.6M | $-8.4M | ||
| Q1 25 | $31.5M | $-6.4M | ||
| Q4 24 | $17.9M | $-44.4M | ||
| Q3 24 | $22.1M | $-21.0M | ||
| Q2 24 | $37.2M | $-108.4M |
| Q1 26 | 35.1% | — | ||
| Q4 25 | 32.8% | 32.6% | ||
| Q3 25 | 31.0% | 36.1% | ||
| Q2 25 | 28.2% | 34.4% | ||
| Q1 25 | 32.1% | 37.6% | ||
| Q4 24 | 30.1% | 33.9% | ||
| Q3 24 | 31.3% | 37.2% | ||
| Q2 24 | 31.5% | 37.0% |
| Q1 26 | 13.4% | — | ||
| Q4 25 | 9.9% | -116.0% | ||
| Q3 25 | 7.5% | 7.0% | ||
| Q2 25 | 6.1% | 4.3% | ||
| Q1 25 | 9.1% | 4.5% | ||
| Q4 24 | 6.6% | 10.0% | ||
| Q3 24 | 7.5% | 7.4% | ||
| Q2 24 | 11.3% | -2.5% |
| Q1 26 | 10.3% | — | ||
| Q4 25 | 6.4% | -127.8% | ||
| Q3 25 | 4.7% | 0.7% | ||
| Q2 25 | 4.2% | -0.8% | ||
| Q1 25 | 6.5% | -0.6% | ||
| Q4 24 | 3.7% | -3.9% | ||
| Q3 24 | 4.6% | -1.9% | ||
| Q2 24 | 6.8% | -10.2% |
| Q1 26 | $0.75 | — | ||
| Q4 25 | $0.44 | $-10.23 | ||
| Q3 25 | $0.30 | $0.05 | ||
| Q2 25 | $0.28 | $-0.06 | ||
| Q1 25 | $0.41 | $-0.05 | ||
| Q4 24 | $0.23 | $-0.32 | ||
| Q3 24 | $0.28 | $-0.15 | ||
| Q2 24 | $0.47 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $106.8M | — |
| Total DebtLower is stronger | $597.4M | — |
| Stockholders' EquityBook value | — | $2.9B |
| Total Assets | $2.7B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $106.8M | — | ||
| Q4 25 | $129.3M | — | ||
| Q3 25 | $103.5M | $432.1M | ||
| Q2 25 | $140.5M | $454.2M | ||
| Q1 25 | $97.5M | $409.9M | ||
| Q4 24 | $121.2M | $558.8M | ||
| Q3 24 | $119.6M | $1.5B | ||
| Q2 24 | $128.0M | $542.8M |
| Q1 26 | $597.4M | — | ||
| Q4 25 | $597.2M | — | ||
| Q3 25 | $597.0M | — | ||
| Q2 25 | $596.8M | — | ||
| Q1 25 | $596.6M | — | ||
| Q4 24 | $596.4M | — | ||
| Q3 24 | $596.2M | — | ||
| Q2 24 | $596.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $2.9B | ||
| Q3 25 | $1.3B | $4.4B | ||
| Q2 25 | $1.3B | $4.5B | ||
| Q1 25 | $1.2B | $4.4B | ||
| Q4 24 | $1.2B | $4.3B | ||
| Q3 24 | $1.3B | $4.6B | ||
| Q2 24 | $1.2B | $4.5B |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.6B | $8.5B | ||
| Q3 25 | $2.5B | $10.1B | ||
| Q2 25 | $2.5B | $10.1B | ||
| Q1 25 | $2.5B | $9.8B | ||
| Q4 24 | $2.4B | $9.6B | ||
| Q3 24 | $2.5B | $11.2B | ||
| Q2 24 | $2.5B | $10.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.46× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.48× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | — | $148.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $55.1M | $175.4M | ||
| Q3 25 | $17.5M | $51.7M | ||
| Q2 25 | $78.6M | $75.9M | ||
| Q1 25 | $28.8M | $-64.5M | ||
| Q4 24 | $55.2M | $312.6M | ||
| Q3 24 | $45.7M | $42.2M | ||
| Q2 24 | $113.6M | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $42.4M | $148.6M | ||
| Q3 25 | $-5.5M | $29.8M | ||
| Q2 25 | $57.1M | $56.7M | ||
| Q1 25 | $5.3M | $-90.0M | ||
| Q4 24 | $35.9M | $274.9M | ||
| Q3 24 | $21.0M | $15.1M | ||
| Q2 24 | $90.3M | $-18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 8.0% | 13.4% | ||
| Q3 25 | -1.1% | 2.9% | ||
| Q2 25 | 11.1% | 5.4% | ||
| Q1 25 | 1.1% | -8.6% | ||
| Q4 24 | 7.5% | 24.2% | ||
| Q3 24 | 4.4% | 1.4% | ||
| Q2 24 | 16.6% | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 2.4% | ||
| Q3 25 | 4.6% | 2.1% | ||
| Q2 25 | 4.2% | 1.8% | ||
| Q1 25 | 4.8% | 2.4% | ||
| Q4 24 | 4.0% | 3.3% | ||
| Q3 24 | 5.1% | 2.5% | ||
| Q2 24 | 4.3% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 0.75× | 6.89× | ||
| Q2 25 | 3.64× | — | ||
| Q1 25 | 0.92× | — | ||
| Q4 24 | 3.08× | — | ||
| Q3 24 | 2.07× | — | ||
| Q2 24 | 3.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KMT
| Americas | $298.3M | 50% |
| EMEA | $174.0M | 29% |
| Asia Pacific | $120.3M | 20% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
